An interventional study of multidisciplinary lessons in Asthma, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.
Among the 177 studies in Asthma with a site in Italy, this one is the 105th largest by planned enrollment of the 130 interventional ones that give a count, is one of 9 that started in 2019, is one of 14 with no phase, reaches primary completion later than 10 of the 28 other live ones, and was the 110th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 6+
Generate Biomedicines · Sites in Italy, United States, Argentina and 16 more countries
Ages 12–80
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–17
Pfizer · Sites in Italy, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Italy, United States, Argentina and 18 more countries
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 402 across the 130 interventional studies, 152 across the 47 observational. Of the 136 that completed or were terminated, 66 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 177 have an industry lead sponsor. The 10 most frequent:
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
Istituti Clinici Scientifici Maugeri SpA has 8 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT04442646Istituti Clinici Scientifici Maugeri SpARole of "Asthma School" in Disease Management | 2026-12-15 |
| NCT06625216Società Italiana di Allergologia, Asma e Immunologia ClinicaSevere Asthma Network Italy | 2027-02-17 |
Add all 10 to your calendar (.ics) → With an account.
Among the 177 studies in Asthma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough. The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections. The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators. Patients affected by severe asthma (\~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy.The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals
Asthma is a chronic inflammatory disease affecting 300 million people worldwide, especially children. In Italy, asthma affects 3 million patients and represents one of the main expenses of the Italian National Heath Care Service. According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough. The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections. The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators. Patients affected by severe asthma (\~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy. More than one third of severe asthma patients receive oral corticosteroids prescriptions, with the risk of severe and irreversible adverse events. Therapy adherence is generally poor when therapeutic regimes are prescribed for chronic diseases, including asthma (4). The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals (4). Several studies have described intervention models focused on education of the patients to symptoms and exacerbations recognition, therapy management, reduction of the exposure to trigger agents and improvement of social and physical activities (5-6). The intervention is not able to make patients independent in disease managing, but can improve the cooperation in asthma management. Another important aspect in asthma management is the quality of the therapeutic intervention: the correct delivery of inhalation therapy is the key for the disease control (3). Specific educational intervention such as "asthma school" can improve symptoms control and reduce; however, up to day, a universal and standardized protocol is not available and further studies are needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
•cognitive impairment
experimental "asthma school" group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
Behavioral: multidisciplinary lessons
Control group will attend control visits every three months.
the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
number of exacerbations
number of exacerbations in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
Time frame: 2 years
ER accesses
ER accesses in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
Time frame: 2 years
number of asthma related hospitalizations
number of asthma related hospitalizations in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
Time frame: 2 years
Asthma control test ACT (0-25)
evaluating asthma symptoms control in Asthma School Group (ASG) compared to Control Group (CG).
Time frame: 2 years
Asthma control questionnaire ACQ (0-6)
evaluating asthma symptoms control in Asthma School Group (ASG) compared to Control Group (CG).
Time frame: 2 years
St. George Respiratory questionnaire SGRQ (0-100)
assessing quality of life in Asthma School Group (ASG) compared to Control Group (CG).
Time frame: 2 years
airways and systemic inflammation
differential cell count in sputum and blood in Asthma School Group (ASG) compared to Control Group (CG). Sputum inflammatio: number eosinophills \>3%, sistemic inflammation: eosiniphils cell count \>250 cell/ul
Time frame: 2 years
respiratory function
Forced Expiratory Volume in 1 second (FEV1) l, %, Forced Volume Capacity (FVC) l,%, FEV1 / FVC% values in Asthma School Group (ASG) compared to Control Group (CG).
Time frame: 2 years
Plan to share: No
Started Apr 2019 (actual). Primary completion is estimated for Dec 2026, 92 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 92 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituti Clinici Scientifici Maugeri SpA →